EP2858984A1 - Inhibiteurs de la réplication de virus de la grippe - Google Patents

Inhibiteurs de la réplication de virus de la grippe

Info

Publication number
EP2858984A1
EP2858984A1 EP13729577.0A EP13729577A EP2858984A1 EP 2858984 A1 EP2858984 A1 EP 2858984A1 EP 13729577 A EP13729577 A EP 13729577A EP 2858984 A1 EP2858984 A1 EP 2858984A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
optionally substituted
independently
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13729577.0A
Other languages
German (de)
English (en)
Inventor
Paul S. Charifson
Mark W. Ledeboer
Michael P. Clark
Michael J. BOYD
Huai Gao
Brian Ledford
Francois Maltais
Emanuele Perola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of EP2858984A1 publication Critical patent/EP2858984A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un composé selon la formule (I) : ou son sel pharmaceutiquement acceptable, les valeurs de la formule développée étant telles que décrites ici. Une composition pharmaceutique comprend une quantité efficace dudit composé ou de son sel pharmaceutiquement acceptable, et un vecteur, un adjuvant ou un véhicule pharmaceutiquement acceptable. L'invention concerne l'utilisation du composé dans l'inhibition de la réplication de virus de la grippe dans un échantillon biologique ou un patient, et dans la réduction de la quantité de virus de la grippe dans un échantillon biologique ou un patient.
EP13729577.0A 2012-06-08 2013-06-07 Inhibiteurs de la réplication de virus de la grippe Withdrawn EP2858984A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261657236P 2012-06-08 2012-06-08
PCT/US2013/044636 WO2013184985A1 (fr) 2012-06-08 2013-06-07 Inhibiteurs de la réplication de virus de la grippe

Publications (1)

Publication Number Publication Date
EP2858984A1 true EP2858984A1 (fr) 2015-04-15

Family

ID=48628957

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13729577.0A Withdrawn EP2858984A1 (fr) 2012-06-08 2013-06-07 Inhibiteurs de la réplication de virus de la grippe

Country Status (2)

Country Link
EP (1) EP2858984A1 (fr)
WO (1) WO2013184985A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57869B1 (sr) 2009-06-17 2018-12-31 Vertex Pharma Inhibitori replikacije virusa gripa
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
SI3068782T1 (sl) 2013-11-13 2018-10-30 Vertex Pharmaceuticals Incorporated Postopki za pripravo inhibitorjev v replikacije virusov gripe
JP6615755B2 (ja) 2013-11-13 2019-12-04 バーテックス ファーマシューティカルズ インコーポレイテッド インフルエンザウイルスの複製の阻害剤
AU2015298876B2 (en) 2014-08-08 2020-02-13 Janssen Sciences Ireland Uc Indoles for use in influenza virus infection
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated インフルエンザウイルスの複製の阻害剤
EP3294717B1 (fr) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Procédés de préparation d'inhibiteurs de réplication des virus de la grippe
US20170100396A1 (en) * 2015-10-07 2017-04-13 F. Hoffmann-La Roche Ag Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza
CA3005514A1 (fr) 2015-11-27 2017-06-01 Janssen Sciences Ireland Uc Indoles heterocycliques a utiliser dans une infection a virus influenza
CA3005921A1 (fr) 2015-12-09 2017-06-15 Sunshine Lake Pharma Co., Ltd. Derives de (pyrrolo[2,3-b]pyridine-3-yl)-pyrimidine substituee et utilisation comme inhibiteurs de la replication du virus de la grippe
AU2017205261B2 (en) 2016-01-07 2021-03-25 Janssen Sciences Ireland Uc Functionalized pentanoic acids for use in influenza viral infections
WO2017125506A1 (fr) * 2016-01-20 2017-07-27 Janssen Sciences Ireland Uc Pyrimidines à substitution aryle à utiliser dans une infection par le virus de la grippe
WO2017133667A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés de pyrimidine et de pyridine et leur utilisation pour traiter ou prévenir la grippe, ou pour atténuer ses symptômes
WO2017133665A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés de 6,7-diazaindazole et de 6,7-diazaindole et leur utilisation dans le traitement, l'atténuation des symptômes ou la prévention de la grippe
WO2017133658A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés de 4,7-diazaindole et 4,7-diazaindazole et leur utilisation pour traiter ou prévenir la grippe, ou pour atténuer ses symptômes
WO2017133670A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés de pyridine et de pyrimidine et leur utilisation dans le traitement, l'atténuation des symptômes ou la prévention de la grippe
WO2017133657A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés de pyridine et de pyrimidine et leur utilisation pour traiter ou prévenir la grippe, ou pour atténuer ses symptômes
WO2017133664A1 (fr) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Dérivés bicycliques de pyridine et de pyrimidine et leur utilisation pour traiter ou prévenir la grippe, ou pour atténuer ses symptômes
CN107759571B (zh) 2016-08-16 2021-03-02 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
US10647693B2 (en) 2016-08-30 2020-05-12 North & South Brother Pharmacy Investment Company Limited Inhibitors of influenza virus replication, application methods and uses thereof
CN106478460B (zh) * 2016-09-28 2018-06-12 衢州学院 一种手性N-Boc-3-氨基-4-芳基-丁酸的合成方法
AU2017376541B2 (en) * 2016-12-15 2021-08-05 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
CN108276401B (zh) 2017-01-05 2020-12-22 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
WO2018157830A1 (fr) 2017-03-02 2018-09-07 Sunshine Lake Pharma Co., Ltd. Inhibiteurs de réplication du virus de la grippe et leurs utilisations
CN108727369B (zh) * 2017-04-25 2023-06-09 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235761A1 (en) 2001-08-14 2004-11-25 Yousuke Furuta Novel virus proliferaton inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue
PL2332940T3 (pl) 2004-03-30 2013-03-29 Vertex Pharma Azaindole użyteczne jako inhibitory JAK i innych kinaz białkowych
WO2006058074A1 (fr) * 2004-11-22 2006-06-01 Vertex Pharmaceuticals Incorporated Pyrrolopyrazines et pyrazolopyrazines convenant inhibiteurs de proteines-kinases
BRPI0706537A2 (pt) 2006-01-17 2011-03-29 Vertex Pharma azaindóis úteis como inibidores de janus cinases
CA2704266A1 (fr) 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated Derives de [1h-pyrazolo[3,4-b]pyridin-4-yl]-phenyle ou -pyridin-2-yle en tant qu'inhibiteurs de la proteine kinase c-theta
WO2010011772A2 (fr) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Inhibiteurs de la pyrazolopyridine kinase tricyclique
JP5631310B2 (ja) 2008-07-23 2014-11-26 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 三環式ピラゾロピリジンキナーゼ阻害剤
AU2009274011B2 (en) 2008-07-23 2014-12-18 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
RS57869B1 (sr) * 2009-06-17 2018-12-31 Vertex Pharma Inhibitori replikacije virusa gripa

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2013184985A1 *

Also Published As

Publication number Publication date
WO2013184985A1 (fr) 2013-12-12

Similar Documents

Publication Publication Date Title
US10875855B2 (en) Inhibitors of influenza viruses replication
US8871774B2 (en) Inhibitors of influenza viruses replication
EP2858984A1 (fr) Inhibiteurs de la réplication de virus de la grippe
EP2651941A1 (fr) Inhibiteurs de réplication de virus de la grippe
DK3141252T3 (en) INHIBITORS OF INFLUENZA VIRUS REPLICATION
US20130345218A1 (en) Inhibitors of influenza viruses replication
OA19823A (en) Inhibitors of influenza viruses replication.
NZ620086B2 (en) Inhibitors of influenza viruses replication
NZ716783B2 (en) Inhibitors of influenza viruses replication

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160105